OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Javier Pinilla‐Ibarz, Josephine Emole, Taiwo Talabi
Biologics (2016), pp. 23-23
Open Access | Times Cited: 17
Javier Pinilla‐Ibarz, Josephine Emole, Taiwo Talabi
Biologics (2016), pp. 23-23
Open Access | Times Cited: 17
Showing 17 citing articles:
Drug-induced pulmonary arterial hypertension: a review
Lohit Garg, Ghulam Akbar, Sahil Agrawal, et al.
Heart Failure Reviews (2017) Vol. 22, Iss. 3, pp. 289-297
Closed Access | Times Cited: 28
Lohit Garg, Ghulam Akbar, Sahil Agrawal, et al.
Heart Failure Reviews (2017) Vol. 22, Iss. 3, pp. 289-297
Closed Access | Times Cited: 28
Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis
Mariana Millan Fachi, Fernanda S. Tonin, Letícia Paula Leonart, et al.
European Journal of Cancer (2018) Vol. 104, pp. 9-20
Closed Access | Times Cited: 27
Mariana Millan Fachi, Fernanda S. Tonin, Letícia Paula Leonart, et al.
European Journal of Cancer (2018) Vol. 104, pp. 9-20
Closed Access | Times Cited: 27
HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
Hélène Losson, Michaël Schnekenburger, Mario Dicato, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 318-318
Open Access | Times Cited: 22
Hélène Losson, Michaël Schnekenburger, Mario Dicato, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 318-318
Open Access | Times Cited: 22
7-Isopenthenyloxycoumarin, Arctigenin, and Hesperidin Modify Myeloid Cell Leukemia Type-1 (Mcl-1) Gene Expression by Hormesis in K562 Cell Line
Zahra Kafi, Hamid Cheshomi, Omid Gholami
Dose-Response (2018) Vol. 16, Iss. 3
Open Access | Times Cited: 13
Zahra Kafi, Hamid Cheshomi, Omid Gholami
Dose-Response (2018) Vol. 16, Iss. 3
Open Access | Times Cited: 13
A Case of Severe, Nilotinib-Induced Liver Injury
Yuliya Belopolsky, David L. Grinblatt, Henry M. Dunnenberger, et al.
ACG Case Reports Journal (2019) Vol. 6, Iss. 2, pp. e00003-e00003
Open Access | Times Cited: 11
Yuliya Belopolsky, David L. Grinblatt, Henry M. Dunnenberger, et al.
ACG Case Reports Journal (2019) Vol. 6, Iss. 2, pp. e00003-e00003
Open Access | Times Cited: 11
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia
Hélène Losson, Sruthi Reddy Gajulapalli, Manon Lernoux, et al.
Pharmacological Research (2020) Vol. 160, pp. 105058-105058
Closed Access | Times Cited: 11
Hélène Losson, Sruthi Reddy Gajulapalli, Manon Lernoux, et al.
Pharmacological Research (2020) Vol. 160, pp. 105058-105058
Closed Access | Times Cited: 11
Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Ana Rita Francisco, Daniela Alves, Cláudio David, et al.
Cardiovascular Toxicology (2018) Vol. 18, Iss. 5, pp. 431-435
Closed Access | Times Cited: 10
Ana Rita Francisco, Daniela Alves, Cláudio David, et al.
Cardiovascular Toxicology (2018) Vol. 18, Iss. 5, pp. 431-435
Closed Access | Times Cited: 10
Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
Kiyotaka Yamazaki, Naohito Inagaki, Daniel Moldaver, et al.
Cancer Science (2020) Vol. 111, Iss. 7, pp. 2526-2535
Open Access | Times Cited: 10
Kiyotaka Yamazaki, Naohito Inagaki, Daniel Moldaver, et al.
Cancer Science (2020) Vol. 111, Iss. 7, pp. 2526-2535
Open Access | Times Cited: 10
Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China
Lixiao Song, Jun Guo, Dan Zhou, et al.
Medicine (2023) Vol. 102, Iss. 50, pp. e36498-e36498
Open Access | Times Cited: 3
Lixiao Song, Jun Guo, Dan Zhou, et al.
Medicine (2023) Vol. 102, Iss. 50, pp. e36498-e36498
Open Access | Times Cited: 3
Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Aaron Ronson, Ariella Tvito, Jacob M. Rowe
Current Treatment Options in Oncology (2017) Vol. 18, Iss. 3
Closed Access | Times Cited: 7
Aaron Ronson, Ariella Tvito, Jacob M. Rowe
Current Treatment Options in Oncology (2017) Vol. 18, Iss. 3
Closed Access | Times Cited: 7
Assessment of Cannabinoids Agonist and Antagonist in Invasion Potential of K562 Cancer Cells
Fatemeh Gholizadeh, Mohammad Hossein Ghahremani, Shima Aliebrahimi, et al.
Iranian Biomedical Journal (2019) Vol. 23, Iss. 2, pp. 153-158
Closed Access | Times Cited: 7
Fatemeh Gholizadeh, Mohammad Hossein Ghahremani, Shima Aliebrahimi, et al.
Iranian Biomedical Journal (2019) Vol. 23, Iss. 2, pp. 153-158
Closed Access | Times Cited: 7
HDAC6 – An Emerging Target against Chronic Myeloid Leukemia?
Hélène Losson, Michaël Schnekenburger, Mario Dicato, et al.
(2020)
Open Access | Times Cited: 7
Hélène Losson, Michaël Schnekenburger, Mario Dicato, et al.
(2020)
Open Access | Times Cited: 7
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
Massimiliano Bonifacio, Vikalp Kumar Maheshwari, Diana Tran, et al.
PharmacoEconomics - Open (2021) Vol. 6, Iss. 1, pp. 95-104
Open Access | Times Cited: 6
Massimiliano Bonifacio, Vikalp Kumar Maheshwari, Diana Tran, et al.
PharmacoEconomics - Open (2021) Vol. 6, Iss. 1, pp. 95-104
Open Access | Times Cited: 6
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions
Lei L. Chen, Jing Zhu, Jonathan A. Schumacher, et al.
PLoS ONE (2017) Vol. 12, Iss. 9, pp. e0184154-e0184154
Open Access | Times Cited: 5
Lei L. Chen, Jing Zhu, Jonathan A. Schumacher, et al.
PLoS ONE (2017) Vol. 12, Iss. 9, pp. e0184154-e0184154
Open Access | Times Cited: 5
Pharmacokinetic Profile of Novel Reduced-Dose Danziten™ (Nilotinib Tablets) versus Tasigna® (Nilotinib Capsules): In Vivo Bioequivalence and Population Pharmacokinetic Analysis
Michael J. Mauro, Jerald P. Radich, Paras Jain, et al.
Research Square (Research Square) (2024)
Open Access
Michael J. Mauro, Jerald P. Radich, Paras Jain, et al.
Research Square (Research Square) (2024)
Open Access
Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China
Vikalp Kumar Maheshwari, Cassandra Slader, Nidhi Dani, et al.
PLoS ONE (2021) Vol. 16, Iss. 10, pp. e0259076-e0259076
Open Access | Times Cited: 2
Vikalp Kumar Maheshwari, Cassandra Slader, Nidhi Dani, et al.
PLoS ONE (2021) Vol. 16, Iss. 10, pp. e0259076-e0259076
Open Access | Times Cited: 2
Chronic Myelogenous Leukemia Presenting with Oculomotor Nerve Palsy: A Case Report and Review of Literatures
Amrit Adhikari Bk, Dinesh Sangroula, Saad Rahmat, et al.
American journal of cancer case reports (2016) Vol. 4, Iss. 1, pp. 51-58
Closed Access
Amrit Adhikari Bk, Dinesh Sangroula, Saad Rahmat, et al.
American journal of cancer case reports (2016) Vol. 4, Iss. 1, pp. 51-58
Closed Access
